Cargando…
Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy
In this study, HER2 RNA aptamers were conjugated to mertansine (DM1) and the anti-cancer effectiveness of the conjugate was evaluated in HER2-overexpressing breast cancer models. The conjugate of HER2 aptamer and anticancer drug DM1 (aptamer-drug conjugate, ApDC) was prepared and analyzed using HPLC...
Autores principales: | Jeong, Hwa Yeon, Kim, Hyeri, Lee, Myunghwa, Hong, Jinju, Lee, Joo Han, Kim, Jeonghyeon, Choi, Moon Jung, Park, Yong Serk, Kim, Sung-Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767363/ https://www.ncbi.nlm.nih.gov/pubmed/33371333 http://dx.doi.org/10.3390/ijms21249764 |
Ejemplares similares
-
Cancer-targeted Nucleic Acid Delivery and Quantum Dot Imaging Using EGF Receptor Aptamer-conjugated Lipid Nanoparticles
por: Kim, Min Woo, et al.
Publicado: (2017) -
Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
por: Kim, Hyun Jung, et al.
Publicado: (2020) -
Development of an aptamer-conjugated fluorescent nanoprobe for MMP2
por: Han, Myoung-Eun, et al.
Publicado: (2014) -
Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer
por: Kim, Min Woo, et al.
Publicado: (2019) -
Using modified aptamers for site specific protein–aptamer conjugations
por: Wang, Ruowen, et al.
Publicado: (2016)